| Not Yet Recruiting | A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ) NCT07101328 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) NCT07519772 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Pred NCT06890884 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | CD70-targeted immunoPET Imaging of Malignant Cancers NCT06852638 | RenJi Hospital | N/A |
| Not Yet Recruiting | A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Ma NCT06573645 | Xia Yi | Phase 3 |
| Active Not Recruiting | A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers NCT06254495 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Withdrawn | Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah NCT06003179 | University Health Network, Toronto | Phase 1 |
| Terminated | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers NCT06120504 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Not Yet Recruiting | Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL NCT06289959 | Second Affiliated Hospital of Soochow University | N/A |
| Recruiting | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies NCT06045910 | Cancer Research UK | Phase 1 / Phase 2 |
| Active Not Recruiting | Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL NCT06093841 | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 2 |
| Unknown | Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Larg NCT05923879 | Ruijin Hospital | — |
| Recruiting | A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphom NCT05800366 | Jennifer Crombie, MD | Phase 2 |
| Active Not Recruiting | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggress NCT05798156 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Active Not Recruiting | Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma NCT05263583 | Cothera Bioscience, Inc | Phase 2 |
| Recruiting | A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma NCT05421663 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Unknown | ChiCGB vs BEAM in High-risk or R/R Lymphomas NCT05466318 | Sichuan University | Phase 3 |
| Unknown | Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL NCT05186558 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Terminated | Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel NCT05199961 | Pack Health | N/A |
| Completed | Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNA NCT04763148 | Herlev Hospital | — |
| Terminated | Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study NCT04982471 | Celgene | — |
| Unknown | PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT NCT04789434 | Ruijin Hospital | Phase 3 |
| Terminated | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Ved NCT04790903 | Hoffmann-La Roche | Phase 1 |
| Completed | Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell NCT05784415 | AIDS Malignancy Consortium | — |
| Completed | A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) NCT04849416 | Eli Lilly and Company | Phase 2 |
| Completed | Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma NCT05318391 | Shanghai Zhongshan Hospital | — |
| Unknown | PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT NCT04799314 | Ruijin Hospital | Phase 3 |
| Completed | Fatigue Reduction Diet in Lymphoma Survivors NCT05327725 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, NCT04660799 | Hoffmann-La Roche | Phase 2 |
| Active Not Recruiting | LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin NCT04446962 | Institut Curie | Phase 1 / Phase 2 |
| Completed | Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated NCT04214444 | University Hospital, Tours | Phase 3 |
| Completed | 18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma NCT04317313 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Unknown | Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DL NCT04237168 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | — |
| Unknown | Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression NCT03977623 | Samsung Medical Center | — |
| Unknown | GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL NCT04021992 | Sun Yat-sen University | Phase 2 |
| Completed | Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory D NCT04022005 | Sun Yat-sen University | Phase 2 |
| Unknown | CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma NCT04271410 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Unknown | Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell NCT04183569 | University Hospital, Bordeaux | — |
| Unknown | Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines NCT05728632 | Giulio Stefanini | Phase 3 |
| Completed | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymp NCT03744676 | Juno Therapeutics, a Subsidiary of Celgene | Phase 2 |
| Completed | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma NCT03682796 | Triphase Research and Development III Corp. | Phase 1 |
| Unknown | A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients NCT03600363 | Ruijin Hospital | Phase 2 |
| Completed | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) NCT03483103 | Juno Therapeutics, a Subsidiary of Celgene | Phase 2 |
| Completed | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin L NCT03357627 | Calithera Biosciences, Inc | Phase 1 |
| Unknown | Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects NCT03629873 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Unknown | Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma ( NCT03373019 | Fudan University | Phase 2 |
| Completed | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies NCT03310619 | Celgene | Phase 1 / Phase 2 |
| Withdrawn | Durvalumab in DLBCL After Autologous Transplant NCT03241017 | Insel Gruppe AG, University Hospital Bern | Phase 2 |
| Completed | Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2) NCT03211702 | Chonbuk National University Hospital | — |
| Active Not Recruiting | Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis NCT03293173 | Nordic Lymphoma Group | Phase 2 |
| Unknown | R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL NCT03018626 | Nanfang Hospital, Southern Medical University | Phase 3 |
| Unknown | Thalidomide Maintenance Treatment in DLBCL NCT03016000 | Nanfang Hospital, Southern Medical University | Phase 3 |
| Terminated | Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or NCT03154710 | Weprom | N/A |
| Terminated | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refrac NCT03135262 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas NCT03049449 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk NCT03003520 | Celgene | Phase 2 |
| Completed | Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL NCT02987400 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Phase 2 |
| Withdrawn | Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DL NCT02653989 | Medivation, Inc. | Phase 2 |
| Completed | Cell-free Circulating DNA in Primary Cutaneous Lymphomas NCT02883517 | University Hospital, Bordeaux | — |
| Terminated | Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas NCT02763254 | Cell Medica Ltd | Phase 2 |
| Unknown | Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell NCT02931201 | Peking University Cancer Hospital & Institute | N/A |
| Unknown | 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma NCT02928861 | Peking University Cancer Hospital & Institute | N/A |
| Unknown | AEDV Registry of Primary Cutaneous Lymphoma NCT03646422 | Fundación Academia Española de Dermatología | — |
| Withdrawn | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ib NCT02743546 | Janssen Research & Development, LLC | Phase 1 |
| Unknown | a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignanci NCT02846584 | Southwest Hospital, China | Phase 2 |
| Withdrawn | A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor NCT02776891 | University of California, San Francisco | Phase 2 |
| Unknown | the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma NCT02737085 | Southwest Hospital, China | Phase 1 / Phase 2 |
| Completed | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) NCT02669017 | ADC Therapeutics S.A. | Phase 1 |
| Completed | To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With R NCT02624492 | Boehringer Ingelheim | Phase 2 |
| Completed | RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor NCT03536039 | Andres J. M. Ferreri | Phase 2 |
| Terminated | Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lym NCT02592876 | Seagen Inc. | Phase 2 |
| Terminated | An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diff NCT02413489 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma NCT02555267 | Chonbuk National University Hospital | — |
| Unknown | R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma NCT02428751 | Wenqi Jiang | Phase 3 |
| Terminated | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies NCT02454270 | Janssen Research & Development, LLC | Phase 1 |
| Completed | A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapse NCT02417285 | Celgene | Phase 1 |
| Terminated | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors NCT02440685 | Asana BioSciences | Phase 1 / Phase 2 |
| Completed | A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or NCT02343536 | Celgene | Phase 1 |
| Completed | A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplant NCT02278796 | Insel Gruppe AG, University Hospital Bern | Phase 2 |
| Terminated | Safety Study of SEA-CD40 in Cancer Patients NCT02376699 | Seagen Inc. | Phase 1 |
| Completed | Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in NCT02285062 | Celgene | Phase 3 |
| Completed | Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory NCT02181218 | Washington University School of Medicine | Phase 1 |
| Completed | Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT02086604 | Washington University School of Medicine | Phase 1 |
| Completed | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) NCT02208037 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Terminated | Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Ly NCT02031419 | Celgene | Phase 1 |
| Unknown | Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM NCT02364050 | Fondazione Italiana Linfomi - ETS | — |
| Terminated | Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Larg NCT01925612 | Seagen Inc. | Phase 2 |
| Completed | A Safety Study of SGN-CD19A for B-Cell Lymphoma NCT01786135 | Seagen Inc. | Phase 1 |
| Completed | A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy NCT01649856 | Hoffmann-La Roche | Phase 3 |
| Unknown | Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients NCT01357733 | The Catholic University of Korea | N/A |
| Completed | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumor NCT01421524 | Celgene | Phase 1 |
| Completed | A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma NCT01421667 | Seagen Inc. | Phase 2 |
| Completed | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab NCT01307267 | Pfizer | Phase 1 |
| Completed | A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib NCT01324596 | University Hospital Southampton NHS Foundation Trust | Phase 3 |
| Unknown | Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Larg NCT01181999 | Chonnam National University Hospital | Phase 2 |
| Unknown | 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Ch NCT01156259 | Chinese Academy of Medical Sciences | Phase 3 |
| Completed | The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL) NCT01266668 | Chonbuk National University Hospital | — |
| Completed | Lenalidomide and R-CHOP in B-cell Lymphoma NCT00901615 | Lymphoma Study Association | Phase 1 / Phase 2 |
| Completed | Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) NCT00864227 | Medical College of Wisconsin | Phase 2 |
| Completed | Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT NCT00849147 | Medical College of Wisconsin | Phase 2 |
| Completed | Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL NCT00655837 | Seagen Inc. | Phase 1 |
| Completed | Coproporphyrine Isomers and Methotrexate Elimination NCT00822432 | Assistance Publique - Hôpitaux de Paris | — |
| Terminated | A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients Wit NCT00529503 | Seagen Inc. | Phase 2 |
| Completed | 90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Ce NCT01157988 | Chonnam National University Hospital | Phase 2 |
| Completed | Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma NCT00435916 | Seagen Inc. | Phase 2 |
| Completed | R-CHOP + GM-CSF for Previously Untreated LCL in Elderly NCT00582725 | University of Wisconsin, Madison | Phase 2 |
| Completed | EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection NCT00006436 | National Cancer Institute (NCI) | Phase 2 |
| Available | Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol NCT04400591 | Juno Therapeutics, a Subsidiary of Celgene | — |